|The evolution of knowledge in the field of health allows modern
society to afford to each of us a life expectancy of longer and longer. As
a result, there is an emergence of new diseases affecting a proportion of
the population more and more important. These diseases, previously
ignored, gather neurodegenerative diseases such as Alzheimer and
Parkinson’s diseases, to point out only the most famous .
|Currently, there are no curative protocols for this type of disease;
only comfort cares are implemented, without any hope of recovery. One
of the reasons related to this lack of appropriate cares must probably
be found in the difficulty of identifying and counting the antigens
responsible for the evolution of these diseases [2,3]. Their diagnosis is
very complex, less sensitive and almost non-reproducible due to the low
concentration of biomarkers of curable patients.
|Research teams working in the medical field but also in microbiology
domain have developed biosensors based on immuno-PCR assays to the
synthesis of new capture or detection antibodies and the amplification
of the signal transmitted by derivatives of the detection antibody .
This pathway is hopeful because it should allow medical teams, once
the diagnosis established in the early stages of the disease to develop the
right curative procedures.
|However, this new generation of biosensors is poorly reproducible
and does not allow its development in hospitals. It appears very quickly
that this non-repeatability of the biosensor is due to a fluctuation of
the concentration of the biomarker in the solution aliquot. This loss
of biological material results of adhesion phenomena on the inner
surfaces of sampling tools, assays (Ependorf, well .....) . A reliable
analytical approach, therefore, requires sharing various expertises of
|Thus, by bringing together researchers in the fields of medicine,
biology, physical-chemistry and materials science, it will be possible to
provide a reliable answer and allow physicians to set up the appropriate
care through the early detection of involved antigens .
|This cross-fertilization between scientific fields so different helps
to improve the effectiveness of these biosensors through a constant
dialogue between the different researchers’ communities. If we want
today to address major societal challenges; it is, therefore, important to
access to scientific information quickly and freely available, as proposed
by the open access journals. For as surprising as it may appear, the field
of biosensors is a multidisciplinary field including the questioning
of the method of detection, the surface properties of the biosensitive
layer, the type of transduction. It is only through this multidisciplinary
approach that scientists will meet society.
- Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.
- Shineman DW, Fillit HM (2009) Meeting the unique challenges of drug discovery for neurodegenerative diseases. BMC Neurol 9: I1.
- Steinmetz KL, Spack EG (2009) The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 9: S2.
- Gofflot S, Deprez M, El Moualij B, Osman A, Thonnart JF, et al. (2005) Immuno-quantitative PCR for prion protein detection in sporadic Creutzfeldt-Jakob disease. Clin Chem 51: 1605-1611.
- Perret-Liaudet A, Pelpel M, Lehmann S, Schraen S, Vanderstichele H.
- Poncin-Epaillard F, Mille C, Debarnot D, Zorzi W, El Moualij B, Coudreuse, et al. (2011) J Biomat Sci: Polym Ed.
- Quadrio I, Tholance Y, Zorzi W, Coudreuse A (2010). Alzheimer’s and Dementia. 6 : e44-e45.